AzTrials
AzTrials

EndoleakNCT02016131

CQDSA in Evaluation of Prognosis After EVAR

An observational study of Endoleak and Aortic Aneurysm, Abdominal, run by Shanghai Zhongshan Hospital at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Re-hospitalization or re-intervention is sometimes necessary to treat type I and type III endoleaks after EVAR for its persistent increasing of pressure in aneurysm lumen. Color-coded quantitative digital subtraction angiography (CQDSA) provides an easy and quick way to post-process the traditional digital subtraction… Read more about this study

Who is it for?
Ages 18 to 90 years
Conditions the study is for
Endoleak, Aortic Aneurysm, Abdominal
How many people
49 participants
Where
1 siteChina
Study dates
Jan 2012to Mar 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients who present type I endoleak after EVAR for AAA.

Who may be able to join

  • Patients who present type I or/and type III endoleak after EVAR for AAA and complete at least 3 months' follow up.

Who cannot join

  • Patients who
  • undergo surgeries which involve the segment covered by EVAR;
  • present connective tissue disease, such as Marfan's Syndrome or vasculitis.
  • present abdominal aortic dissection.
  • present AAA rupture.
  • die from non aneurysm-reltated reasons or are lost during follow up.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Zhongshan Hospital

    Shanghai, 200032

Other trials in China

About this study

Official title: Application of Color-coded Quantitative Digital Subtraction Angiography in Evaluation of Prognosis After Endovascular Repairment of Abdominal Aortic Aneurysm

Re-hospitalization or re-intervention is sometimes necessary to treat type I and type III endoleaks after EVAR for its persistent increasing of pressure in aneurysm lumen. Color-coded quantitative digital subtraction angiography (CQDSA) provides an easy and quick way to post-process the traditional digital subtraction angiography (DSA) which converts the peak time of the maximal contrast medium intensity into a single polychromatic image. With the help of CQDSA, a quantitative evaluation of the endoleak hemodynamics and a risk analysis of the type I or type III endoleak could be performed during the EVAR procedure. This approach may offer an objective assessment of the needs for immediate re-intervention, conservative therapy or treatment endpoint in the future.

Read the detailed description

Intra-procedural DSA series are transferred to a research workstation to generate the color-coded images and make quantitative measurements. Region of interest (ROI) measurements are performed equivalently in the endoleak and the aorta after the image generation. There are three kinds of ROIs including a small circle area with the shortest time to peak, a circle area with peak contrast intensity and the whole endoleak area. The ROI and a reference at the same latitude within the aorta are selected to undergo measurement which reflected the endoleak hemodynamics of the endoleak to the utmost extent.

The following parameters will be acquired through the CQDSA for analysis.

  1. Time-versus-ROI contrast intensity graph. The graph contains one endoleak ROI flow curve and one reference aortic flow curve (Ref). The x-axis shows time from 0 second to the maximum frame time of the image. The y-axis shows the sum of pixel intensities, namely total contrast, representing the contrast concentration within the ROI.
  2. ROI Peak/Ref Peak. It is the ratio of intensity peak between the endoleak and the reference in the aorta.
  3. ROI TTP (Time to peak). Peak time of ROI in the vicinity of endoleak entry.
  4. ROI AUC/Ref AUC. Area under curve (AUC) is calculated through Time-versus-ROI contrast intensity graph. The parameter here is the ratio of ROI AUC in endoleak to the reference.
Keywords
endoleak, EVAR, AAA, CQDSA
Medical subject headings
Endoleak, Aortic Aneurysm, Abdominal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02016131
Study groupRoleWhat they receive
none endoleak eventsPatients who have no further endoleaks related adverse events including aneurysm enlargement and rupture or persistent endoleaks.
Endoleak eventsPatients who undergo endoleaks related adverse events or persistent endoleaks during follow up.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time-versus-ROI contrast intensity graph.

    The graph contains one endoleak ROI flow curve and one reference aortic flow curve (Ref). The x-axis shows time from 0 second to the maximum frame time of the image. The y-axis shows the sum of pixel intensities, namely total contrast, representing the contrast concentration within the ROI.

    Measured: 15 seconds

  2. ROI Peak/Ref Peak

    It is the ratio of intensity peak between the endoleak and the reference in the aorta.

    Measured: 15 seconds

  3. ROI TTP (Time to peak)

    Peak time of ROI in the vicinity of endoleak entry

    Measured: 15 seconds

  4. ROI AUC/Ref AUC

    Area under curve (AUC) is calculated through Time-versus-ROI contrast intensity graph. The parameter here is the ratio of ROI AUC in endoleak to the reference.

    Measured: 15 seconds

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Dec 2013 (estimated)
  2. Study startJan 2012
  3. Primary completionSep 2014
  4. Study completionMar 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
49 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02016131
Sponsor's protocol ID
CQDSA_EVAR
Status last verified
May 2015
First submitted
14 Dec 2013
Last updated
21 Aug 2025
Results posted
No
Data monitoring committee
No

Publications

  • Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D, Krupski WC, Barone GW, Acher CW, Ballard DJ. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 1997 Mar 15;126(6):441-9. doi: 10.7326/0003-4819-126-6-199703150-00004.

    PubMed 9072929
  • Thompson AR, Cooper JA, Ashton HA, Hafez H. Growth rates of small abdominal aortic aneurysms correlate with clinical events. Br J Surg. 2010 Jan;97(1):37-44. doi: 10.1002/bjs.6779.

    PubMed 20013940
  • Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT; UK Small Aneurysm Trial Participants. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004 Jul 6;110(1):16-21. doi: 10.1161/01.CIR.0000133279.07468.9F. Epub 2004 Jun 21.

    PubMed 15210603
  • Reed WW, Hallett JW Jr, Damiano MA, Ballard DJ. Learning from the last ultrasound. A population-based study of patients with abdominal aortic aneurysm. Arch Intern Med. 1997 Oct 13;157(18):2064-8. doi: 10.1001/archinte.157.18.2064.

    PubMed 9382661
  • Scott RA, Ashton HA, Lamparelli MJ, Harris GJ, Stevens JW. A 14-year experience with 6 cm as a criterion for surgical treatment of abdominal aortic aneurysm. Br J Surg. 1999 Oct;86(10):1317-21. doi: 10.1046/j.1365-2168.1999.01227.x.

    PubMed 10540141
  • Scott RA, Wilson NM, Ashton HA, Kay DN. Is surgery necessary for abdominal aortic aneurysm less than 6 cm in diameter? Lancet. 1993 Dec 4;342(8884):1395-6. doi: 10.1016/0140-6736(93)92756-j.

    PubMed 7901685
  • Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet. 1998 Nov 21;352(9141):1649-55.

    PubMed 9853436
  • Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW, Ballard DJ, Messina LM, Gordon IL, Chute EP, Krupski WC, Busuttil SJ, Barone GW, Sparks S, Graham LM, Rapp JH, Makaroun MS, Moneta GL, Cambria RA, Makhoul RG, Eton D, Ansel HJ, Freischlag JA, Bandyk D; Aneurysm Detection and Management Veterans Affairs Cooperative Study Group. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002 May 9;346(19):1437-44. doi: 10.1056/NEJMoa012573.

    PubMed 12000813
  • Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, Waltham M, van Herwaarden JA, Holt PJ, van Keulen JW, Rantner B, Schlosser FJ, Setacci F, Ricco JB; European Society for Vascular Surgery. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg. 2011 Jan;41 Suppl 1:S1-S58. doi: 10.1016/j.ejvs.2010.09.011. No abstract available.

    PubMed 21215940
  • Jens S, Marquering HA, Koelemay MJ, Reekers JA. Perfusion angiography of the foot in patients with critical limb ischemia: description of the technique. Cardiovasc Intervent Radiol. 2015 Feb;38(1):201-5. doi: 10.1007/s00270-014-1036-5. Epub 2014 Dec 13.

    PubMed 25501266
  • Benndorf G. Color-coded digital subtraction angiography: the end of a monochromatic era? AJNR Am J Neuroradiol. 2010 May;31(5):925-7. doi: 10.3174/ajnr.A2077. Epub 2010 Apr 15. No abstract available.

    PubMed 20395396
  • Mehndiratta A, Knopp MV, Zechmann CM, Owsijewitsch M, von Tengg-Kobligk H, Zamecnik P, Kauczor HU, Choyke PL, Giesel FL. Comparison of diagnostic quality and accuracy in color-coded versus gray-scale DCE-MR imaging display. Int J Comput Assist Radiol Surg. 2009 Sep;4(5):457-62. doi: 10.1007/s11548-009-0356-4. Epub 2009 Jun 4.

    PubMed 20033528
  • Tenjin H, Asakura F, Nakahara Y, Matsumoto K, Matsuo T, Urano F, Ueda S. Evaluation of intraaneurysmal blood velocity by time-density curve analysis and digital subtraction angiography. AJNR Am J Neuroradiol. 1998 Aug;19(7):1303-7.

    PubMed 9726473
  • Strother CM, Bender F, Deuerling-Zheng Y, Royalty K, Pulfer KA, Baumgart J, Zellerhoff M, Aagaard-Kienitz B, Niemann DB, Lindstrom ML. Parametric color coding of digital subtraction angiography. AJNR Am J Neuroradiol. 2010 May;31(5):919-24. doi: 10.3174/ajnr.A2020. Epub 2010 Feb 18.

    PubMed 20167651
  • Khanafer KM, Bull JL, Upchurch GR Jr, Berguer R. Turbulence significantly increases pressure and fluid shear stress in an aortic aneurysm model under resting and exercise flow conditions. Ann Vasc Surg. 2007 Jan;21(1):67-74. doi: 10.1016/j.avsg.2006.10.009.

    PubMed 17349339

Questions about this trial

What is this clinical trial studying?

An observational study of Endoleak and Aortic Aneurysm, Abdominal, run by Shanghai Zhongshan Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time-versus-ROI contrast intensity graph. (time frame: 15 seconds). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02016131, which also lists 19 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in